e-learning
resources
Berlin 2008
Monday, 06.10.2008
Improving asthma and anti-allergic therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of a protocol to select patients for omalizumab treatment
H. McLoughlin, A. Hart-Thomas, J. Slough, T. Capstick (Leeds, United Kingdom)
Source:
Annual Congress 2008 - Improving asthma and anti-allergic therapy
Session:
Improving asthma and anti-allergic therapy
Session type:
Thematic Poster Session
Number:
2014
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. McLoughlin, A. Hart-Thomas, J. Slough, T. Capstick (Leeds, United Kingdom). Use of a protocol to select patients for omalizumab treatment. Eur Respir J 2008; 32: Suppl. 52, 2014
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Use of Rituximab in the treatment of CTD-ILD in RA patients.
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Comparison of initial drug treatment of incident COPD patients with German treatment guidelines
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Use of relievers in patients with severe asthma on biologic therapy –a multidisciplinary approach
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020
Evaluation of adherence of patients with asthma to treatment by single combination inhaler
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment
Source: Eur Respir J 2015; 45: 260-262
Year: 2015
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
The use of high-dose inhaled corticosteroids and add-on therapy in children in the UK: an observational study of 4332 patients
Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Year: 2004
High-dose inhaled corticosteroids and add-on therapy use in adults in the UK: an observational study of 22,027 patients
Source: Annual Congress 2004 - Primary care: asthma
Year: 2004
Use of antidepressive agents in COPD patients: experience in a large Canadian cohort
Source: Annual Congress 2008 - Comorbidities in COPD
Year: 2008
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack)
Source: International Congress 2017 – Medical education, web and internet
Year: 2017
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept